Hillsborough, NC, United States of America

Scott P Runyon

USPTO Granted Patents = 19 

 

 

Average Co-Inventor Count = 5.2

ph-index = 4

Forward Citations = 30(Granted Patents)


Location History:

  • Hillsborough, NC (US) (2013 - 2023)
  • Research Triangle Park, NC (US) (2011 - 2024)

Company Filing History:


Years Active: 2011-2024

Loading Chart...
Loading Chart...
Loading Chart...
19 patents (USPTO):Explore Patents

Title: Scott P. Runyon: Innovator in Apelin Receptor Agonists

Introduction

Scott P. Runyon, based in Hillsborough, NC, is a prominent innovator with a remarkable portfolio of 19 patents. His work primarily revolves around the development of novel compounds that target the apelin receptor, a crucial component in various physiological processes.

Latest Patents

Runyon's recent patents include significant advancements in the field of pharmacology. Notably, he has developed two related disclosures titled "Heterocyclic Apelin Receptor (APJ) Agonists and Uses Thereof" and "Apelin Receptor (APJ) Agonists and Uses Thereof." These disclosures focus on agonists with heterocyclic cores designed to enhance the functionality of the apelin receptor, showcasing their potential therapeutic applications.

Career Highlights

Throughout his career, Runyon has been associated with esteemed institutions such as the Research Triangle Institute and the United States of America, as represented by the Secretary of the Department of Health and Human Services. His work has significantly contributed to the understanding and development of new receptor-targeting therapeutics, playing a pivotal role in advancing medical science.

Collaborations

Scott has collaborated with notable researchers, including James Barnwell Thomas and Sanju Narayanan. These partnerships have fostered a rich environment for innovation, leading to the development of crucial technologies and therapeutics aimed at improving human health.

Conclusion

Scott P. Runyon exemplifies the spirit of innovation in the pharmaceutical field with his extensive patent portfolio and collaborations. His contributions, particularly in the realm of apelin receptor agonists, demonstrate his commitment to enhancing therapeutic options available for various health conditions. As advancements continue to unfold, Runyon's work remains at the forefront of scientific discovery.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…